While the subtypes seen within the CD8+ T cell populations were also relatively stable across patients and cancer subtypes, the observed variability between some patients – for example BCB‐0139 and BCB‐0066 – may be due to differences in treatment response. The gene discussed is CD8A; the disease is cancer.